Zelquistinel in the Treatment of Adults With Major Depressive Disorder

Summary

The purpose of this study is to evaluate the efficacy and safety of AGN-241751 in participants with Major Depressive Disorder

Timeline

Start

2018-11-08

Primary completion

2019-10-23

Completion

2019-10-23

Outcome

Missed primary endpoint

registry AGN-241751 3mg Daily vs Placebo Daily; p = 0.98 NCT03726658 ↗

registry AGN-241751 3mg Two Times Per Day vs Placebo 2 Times Per Day; p = 0.43 NCT03726658 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Zelquistinel	Small molecule	3 mg	Oral
Subject	Zelquistinel	Small molecule	10 mg	Oral
Subject	Zelquistinel	Small molecule	25 mg	Oral

Indications